Age-related macular degeneration (AMD) is one of the leading causes of vision impairment and blindness in the elderly worldwide, with its prevalence increasing significantly with age. The pathogenesis of AMD is multifactorial, involving genetic predisposition, environmental risk factors, chronic inflammation, and mitochondrial dysfunction. In recent years, mitophagy has emerged as a critical mechanism for maintaining mitochondrial quality control, energy homeostasis, and cellular integrity in retinal pigment epithelium (RPE) and photoreceptor cells. Dysregulated mitophagy leads to the accumulation of damaged mitochondria, excessive reactive oxygen species, and metabolic imbalance, thereby triggering RPE dysfunction, inflammatory amplification, and choroidal neovascularization, which drive AMD progression. Both classical pathways (e.g., PINK1/Parkin) and non-classical pathways (e.g., BNIP3, FUNDC1) have been implicated in AMD pathophysiology. Molecules such as Parkin and p62, as well as multimodal imaging features, hold promise as early biomarkers for disease monitoring. Preclinical studies have shown that small-molecule activators (e.g., Urolithin A, Spermidine) and mitochondria-targeted antioxidants (e.g., MitoQ, SkQ1) can restore mitophagy and alleviate RPE damage. However, current evidence remains limited, as large-scale, long-term clinical trials are lacking. Challenges in drug delivery efficiency, safety, patient stratification, and clinical monitoring tools still hinder translation into practice. Future research should focus on biomarker-driven precision interventions, multicenter randomized controlled trials, and individualized therapeutic strategies. Overall, mitophagy research is transitioning from mechanistic exploration to clinical translation, with promising potential to enable early diagnosis, disease stratification, and precision management of AMD.